[UPDATED] CURATIVE BIOTECHNOLOGY ANNOUNCES OCULAR TOLERANCE EVALUATION OF METFORMIN EYE DROP FORMULATIONS FOR TREATMENT OF MACULAR DEGENERATION

Rhea-AI Summary

Curative Biotechnology (CUBT) has advanced its metformin eye drop formulations into ocular tolerance evaluation, marking a critical step toward human clinical trials. The studies will assess tolerability and pharmacokinetics, focusing on safety and ocular tissue distribution. This research will support future Good Laboratory Practice toxicology studies required for an Investigational New Drug (IND) filing. As part of the evaluation, metformin's plasma concentration will also be measured to ensure systemic safety. The company's innovative approach targets rare diseases, aiming for accelerated development paths.

Positive

• Advancement into ocular tolerance studies for metformin eye drop formulations, indicating progress toward human clinical trials.
• Focus on pharmacokinetics and safety, supporting future IND filings.

Negative

• CUBT is not yet generating revenues, posing a risk to financial stability.
• Forward-looking statements highlight inherent risks and uncertainties in achieving operational cash flow.

Company’s First In-license Pipeline Product to Enter Pre-clinical Studies

Boca Raton, FL, Nov. 24, 2021 (GLOBE NEWSWIRE) -- Curative Biotechnology, Inc. (OTC: CUBT) (“Curative Biotech” or the “Company”), a development-stage biomedical company focused on novel treatments for rare diseases and conditions, announced today the company has advanced into ocular tolerance evaluation of various metformin eye drop formulations. 

As a significant step towards moving into human clinical trials, the current studies focus on tolerability and pharmacokinetics which will assess the ocular tissue distribution after topical ocular delivery of metformin. These studies will aid in optimization of the formulation and build evidence to ensure adequate exposure and safety via topical ocular delivery, which will support the company to move into Good Laboratory Practice (GLP) toxicology studies for an IND filing.

Ocular tolerance includes observations at dosing, general clinical observations twice daily (evaluation of behavior/clinical signs with particular attention paid to the eyes), ophthalmic examinations by a board-certified veterinary ophthalmologist according to the modified Hackett-McDonald scoring scale, and ocular histopathology.

Paul Michaels, Chairman and President of Curative Biotech said, “Significantly for our future IND filing, we are also measuring metformin concentration in the plasma to evaluate systemic exposure. We are conducting studies which will be followed with histological analysis.”

Future Curative Biotechnology Press Releases and Industry Updates

Interested investors and shareholders will receive press releases and industry updates by sending an e-mail to ir@curativebiotech.com.

About Curative Biotechnology, Inc. http://curativebiotech.com

Curative Biotech is a development-stage biomedical company focusing on novel treatments for rare or currently unmet medical needs. Curative Biotech is focused on therapies with potentially accelerated development paths resulting from either the disease, the nature of the therapeutic itself, or the stage of clinical development. At the heart of the Company is a product development engine that rests on our unique S.O.A.R. filter (Science, Opportunity, Acceleration, Rare Disease.) At Curative Biotech, we envision a world where all patients have a therapeutic option.

Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934. CUBT is not yet generating revenues. Although forward-looking statements in this release reflect the good faith judgment of management, forward-looking statements are inherently subjected to known, unknown risks and uncertainties that may cause actual results to be materially different from those discussed in these forward-looking statements, including but not limited our ability to generate sufficient market acceptance for our products and services, our ability to generate sufficient operating cash flow, and general economic conditions. Readers are urged to carefully review and consider the various disclosures made by us in our reports filed with OTC Markets from time to time which attempt to advise interested parties of the risks and factors that may affect our business, financial condition, results of operation and cash flows. If one or more of these risks or uncertainties materialize, or if the underlying assumptions prove incorrect, our actual results may vary materially from those expected or projected. Readers are urged not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. We assume no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.

Contact:
Steve Chizzik
Investor Relations
Curative Biotech (CUBT)
201-454-5845
ir@curativebiotech.com

FAQ

What is the latest development from Curative Biotechnology (CUBT) regarding its metformin eye drop formulations?

Curative Biotechnology has moved into ocular tolerance evaluation studies for its metformin eye drop formulations, aiming for human clinical trials.

What studies are being conducted by Curative Biotechnology for its eye drop products?

The company is conducting studies on tolerability and pharmacokinetics to ensure ocular safety and effective tissue distribution of metformin.

What are the future plans for Curative Biotechnology's eye drop formulations?

The studies will support the company in moving to Good Laboratory Practice (GLP) toxicology studies necessary for an IND filing.

Are there any financial concerns for Curative Biotechnology (CUBT) mentioned in the recent press release?

Yes, the press release notes that CUBT is not yet generating revenues, which presents a financial risk.